SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : PARANOID! TIRED OF TALKING TO YOURSELF? LET'S TALK(TTP)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: NeuroInvestment who wrote (264)1/21/1999 12:02:00 AM
From: John Metcalf  Read Replies (2) of 626
 
"no real news has emerged other than Novartis reaffirming what was already in print--and enlarging the total Phase III target from 2600 to 3300"

That was big news to me. First, Novartis is spending big money, therefore sees big value.

Second, only 600 of these trial participants will be in the US (18%). This means that Novartis sees value beyond lessening of the agranulocytosis side effect of their Clozaril.

In the US, weekly blood levels are required for Clozaril users, and this accounts for more than half the annual cost of use. In Europe, the standard of care is to reduce lab work if no problems are encountered in the first few months. If Novartis had weighted the trials heavily towards the US, I would have concluded that they were aiming at a Clozaril replacement with lower monitoring costs. However, the ZEUS trial is slanted 82% towards the rest of the world, so I suspect Novartis is anticipating other advantages.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News